Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

Clotrimazole 1% addition to antifungal monograph requested by Schering-Plough.

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

CLOTRIMAZOLE 1% ADDITION TO ANTIFUNGAL MONOGRAPH REQUESTED by Schering-Plough HealthCare Products in a Nov. 27 citizen petition. The firm is requesting that FDA revise the final monograph for topical antifungal OTC drug products to include clotrimazole 1% for the same indications as other imidazole active ingredients: "the treatment of athlete's foot, jock itch and ringworm and for use in the treatment of superficial skin infections caused by yeast (Candida albicans)." The latter indication is for professional labeling only.
Table

View full table

Advertisement
Advertisement

Topics

Advertisement
Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS086446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By